BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 18957720)

  • 21. Automated real-time PCR to determine K-ras codon 12 mutations in non-small cell lung cancer: comparison with immunohistochemistry and clinico-pathological features.
    Hilbe W; Dlaska M; Duba HC; Dirnhofer S; Eisterer W; Oberwasserlechner F; Mildner A; Schmid T; Kühr T; Wöll E
    Int J Oncol; 2003 Oct; 23(4):1121-6. PubMed ID: 12963994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.
    Schiller JH; Adak S; Feins RH; Keller SM; Fry WA; Livingston RB; Hammond ME; Wolf B; Sabatini L; Jett J; Kohman L; Johnson DH
    J Clin Oncol; 2001 Jan; 19(2):448-57. PubMed ID: 11208838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
    Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
    Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lung cancer and past occupational exposure to asbestos. Role of p53 and K-ras mutations.
    Husgafvel-Pursiainen K; Karjalainen A; Kannio A; Anttila S; Partanen T; Ojajärvi A; Vainio H
    Am J Respir Cell Mol Biol; 1999 Apr; 20(4):667-74. PubMed ID: 10100998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of telomerase hTERT in human non-small cell lung cancer and its correlation with c-myc gene.
    Geng Z; Zhang D; Liu Y
    Chin Med J (Engl); 2003 Oct; 116(10):1467-70. PubMed ID: 14570602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between downexpression of MiR-203 and poor prognosis in non-small cell lung cancer patients.
    Tang R; Zhong T; Dang Y; Zhang X; Li P; Chen G
    Clin Transl Oncol; 2016 Apr; 18(4):360-8. PubMed ID: 26307752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma.
    Cho JY; Kim JH; Lee YH; Chung KY; Kim SK; Gong SJ; You NC; Chung HC; Roh JK; Kim BS
    Cancer; 1997 Feb; 79(3):462-7. PubMed ID: 9028355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytoplasmic Ape1 expression elevated by p53 aberration may predict survival and relapse in resected non-small cell lung cancer.
    Wu HH; Chu YC; Wang L; Tsai LH; Lee MC; Chen CY; Shieh SH; Cheng YW; Lee H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S336-47. PubMed ID: 22688662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women.
    Nelson HH; Christiani DC; Mark EJ; Wiencke JK; Wain JC; Kelsey KT
    J Natl Cancer Inst; 1999 Dec; 91(23):2032-8. PubMed ID: 10580029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
    Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
    PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung.
    Li ZH; Zheng J; Weiss LM; Shibata D
    Am J Pathol; 1994 Feb; 144(2):303-9. PubMed ID: 8311114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Expression and significance of telomerase reverse transcriptase and its regulators in non-small cell lung carcinoma].
    Chen TX; Xiong YY; Liu L
    Ai Zheng; 2004 Mar; 23(3):273-7. PubMed ID: 15025956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer.
    Graziano SL; Gamble GP; Newman NB; Abbott LZ; Rooney M; Mookherjee S; Lamb ML; Kohman LJ; Poiesz BJ
    J Clin Oncol; 1999 Feb; 17(2):668-75. PubMed ID: 10080613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas.
    Soung YH; Lee JW; Kim SY; Seo SH; Park WS; Nam SW; Song SY; Han JH; Park CK; Lee JY; Yoo NJ; Lee SH
    Virchows Arch; 2005 May; 446(5):483-8. PubMed ID: 15815931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
    Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
    Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. K-ras and p53 mutations and overexpressions as prognostic factors in female rectal carcinoma.
    Hirvikoski P; Auvinen A; Servomaa K; Kiuru A; Rytömaa T; Makkonen K; Kosma VM
    Anticancer Res; 1999; 19(1B):685-91. PubMed ID: 10216477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of K-ras gene mutations in tumour and sputum DNA of patients with lung cancer.
    Zhang LF; Gao WM; Gealy R; Weissfeld J; Elder E; Whiteside TL; Keohavong P
    Biomarkers; 2003; 8(2):156-61. PubMed ID: 12775500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic implications of miR-16 expression levels in resected non-small-cell lung cancer.
    Navarro A; Diaz T; Gallardo E; Viñolas N; Marrades RM; Gel B; Campayo M; Quera A; Bandres E; Garcia-Foncillas J; Ramirez J; Monzo M
    J Surg Oncol; 2011 Apr; 103(5):411-5. PubMed ID: 21400525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GSTM1, P53 and K-ras molecular detection in resectable non-small cell lung cancer by denaturing gradient gel electrophoresis-bronchoalveolar lavage fluid analysis.
    Curigliano G; Ferretti G; Mandalà M; De Pas T; Calabrò MG; Solli P; Noberasc C; de Braud F
    Anticancer Res; 2001; 21(5):3461-9. PubMed ID: 11848510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.